This article is more than 5 years old. Information may no longer be current.
Investigational integrin antagonist may treat dry eye symptoms
An investigational integrin antagonist relieved symptoms of dry eye disease within 2 weeks of treatment and was found to be safe and effective when administered over 84 days, according to a study.
“This study of a novel investigational integrin antagonist (SAR 1118) has demonstrated its ability to improve both signs and symptoms of dry eye disease and may represent a faster-acting second-generation agent for the treatment of dry eye,” the study authors said.
The phase 2, randomized, double-masked, placebo-controlled study compared SAR 1118 to placebo in 230 participants with dry eye disease at five U.S. sites from August 2009 through February 2010. Three different concentrations of SAR 1118 — 0.1%, 1% and 5% — administered twice daily were evaluated.
Ocular signs and symptoms were assessed at 14, 42 and 84 days. The primary outcome measure was inferior corneal staining score at day 84.
Results showed that SAR 1118 significantly improved total Ocular Surface Disease Index, visual-related function and corneal staining scores compared to placebo. The investigators observed improvement in dry eye symptoms and tear production as early as 14 days.
No serious ocular adverse events were reported. Mild adverse events at the instillation site were associated with the 5% concentration of SAR 1118 but were limited to the initial dose.